BridgeBio Pharma (BBIO) reported a Q1 net loss late Tuesday of $0.88 per diluted share, compared with a loss of $0.20 a year earlier.
Analysts polled by FactSet expected a loss of $0.94.
Revenue for the quarter ended March 31 was $116.6 million, down from $211.1 million a year earlier. Analysts surveyed by FactSet expected $60.2 million.
The company's shares were up more than 7% in recent after-hours activity.